References
- Abbott NJ Patabendige AA Dolman DE Yusof SR Begley DJ . Structure and function of the blood–brain barrier. Neurobiol. Dis.37, 13–25 (2010).
- Stanimirovic DB Kemmerich K Haqqani AS Farrington GK . Engineering and pharmacology of blood–brain barrier-permeable bispecific antibodies. Adv. Pharmacol.71, 301–335 (2014).
- Jones AR Shusta EV . Blood–brain barrier transport of therapeutics via receptor-mediation. Pharm. Res.24, 1759–1771 (2007).
- Pardridge WM Buciak JL Friden PM . Selective transport of an anti-transferrin receptor antibody through the blood–brain barrier in vivo. J. Pharmacol. Exp. Ther.259, 66–70 (1991).
- Coloma MJ Lee HJ Kurihara A et al. Transport across the primate blood–brain barrier of a genetically engineered chimeric monoclonal antibody to the human insulin receptor. Pharm. Res.17 (3), 266–274 (2000).
- Yu YJ Zhang Y Kenrick M et al. Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci. Transl. Med.3, 84ra44 (2011).
- Niewoehner J Bohrmann B Collin L et al. Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle. Neuron81, 49–60 (2014).
- Gabathuler R . Development of new peptide vectors for the transport of therapeutic across the blood–brain barrier. Ther. Deliv.1 (4), 571–586 (2010).
- Regina A Demeule M Tripathy S et al. ANG4043, a novel brain-penetrant peptide-mAb conjugate, is efficacious against HER2-positive intracranial tumors in mice. Mol. Cancer Ther.14 (1), 129–140 (2015).
- Ohshima-Hosoyama S Simmons HA Goecks N et al. A monoclonal antibody-GDNF fusion protein is not neuroprotective and is associated with proliferative pancreatic lesions in parkinsonian monkeys. PLoS ONE7, e39036 (2012).
- Couch JA Yu YJ Zhang Y et al. Addressing safety liabilities of TfR bispecific antibodies that cross the blood–brain barrier. Sci. Transl. Med.5, 183ra57, 1–12 (2013).
- Hanzatian DK . Blood–brain barrier (BBB) penetrating dual specific binding proteins for treating brain and neurological diseases. Presented at : World Preclinical Congress. Boston, MA, USA, 10–12 June 2015.
- Tanha J Muruganandam A Stanimirovic D . Phage display technology for identifying specific antigens on brain endothelial cells. Methods Mol. Med.89, 435–449 (2003).
- Muruganandam A Tanha J Narang S Stanimirovic D . Selection of phage-displayed llama single-domain antibodies that transmigrate across human blood–brain barrier endothelium. FASEB J.16, 240–242 (2002).
- Farrington GK Caram-Salas N Haqqani AS et al. A novel platform for engineering blood–brain barrier-crossing bispecific biologics. FASEB J.28, 4764–4778 (2014).
- Bien-Ly N Yu YJ Bumbaca D et al. Transferrin receptor (TfR) trafficking determines brain uptake of TfR antibody affinity variants. J. Exp. Med.211, 233–244 (2014).
- Haqqani AS Delaney CE Tremblay T-L Sodja C Sandhu JK Stanimirovic DB . Method for isolation and molecular characterization of extracellular microvesicles released from brain endothelial cells. Fluids Barriers CNS10, 4 (2013).
- Hladky SB Barrand MA . Mechanisms of fluid movement into, through and out of the brain: evaluation of the evidence. Fluids Barriers CNS11, 26 (2014).
- Wolak DJ Pizzo ME Thorne RG . Probing the extracellular diffusion of antibodies in brain using in vivo integrative optical imaging and ex vivo fluorescence imaging. J. Control. Release197, 78–86 (2015).
- Boado RJ Ka-Wai Hui E Zhiqiang Lu J Pardridge WM . Insulin receptor antibody-iduronate 2-sulfatase fusion protein: pharmacokinetics, anti-drug antibody, and safety pharmacology in Rhesus monkeys. Biotechnol. Bioeng.111 (11), 2317–2325 (2014).